Despite a mixed fourth-quarter revenue performance, British pharmaceutical giant GSK remains optimistic about its long-term growth prospects, particularly with its ambitious revenue target for 2031.

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...